Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.94)
# 120
Out of 5,182 analysts
51
Total ratings
76.47%
Success rate
61.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Buy | $18 | $5.54 | +224.91% | 2 | Apr 10, 2026 | |
| NBP NovaBridge Biosciences | Reiterates: Buy | $9 | $2.43 | +270.37% | 3 | Apr 8, 2026 | |
| CGON CG Oncology | Maintains: Buy | $80 → $100 | $66.82 | +49.66% | 6 | Apr 7, 2026 | |
| AURA Aura Biosciences | Reiterates: Buy | $22 | $6.96 | +216.09% | 2 | Mar 30, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Neutral | $60 → $53 | $52.95 | +0.09% | 3 | Mar 25, 2026 | |
| STRO Sutro Biopharma | Upgrades: Buy | $10 → $28 | $33.59 | -16.64% | 2 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Buy | $15 → $20 | $19.15 | +4.44% | 3 | Mar 13, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $5.21 | +149.52% | 1 | Mar 10, 2026 | |
| ENGN enGene Therapeutics | Reiterates: Buy | $25 | $7.20 | +247.22% | 3 | Mar 9, 2026 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $58 | $46.29 | +25.30% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $7.29 | +105.76% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $23.49 | +70.29% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $4.99 | +360.92% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.83 | +381.93% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.31 | +434.35% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $21.00 | +90.48% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $10.08 | +296.83% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $6.29 | +265.66% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $54.02 | +94.37% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $11.01 | +81.65% | 1 | Aug 8, 2025 |
Verastem
Apr 10, 2026
Reiterates: Buy
Price Target: $18
Current: $5.54
Upside: +224.91%
NovaBridge Biosciences
Apr 8, 2026
Reiterates: Buy
Price Target: $9
Current: $2.43
Upside: +270.37%
CG Oncology
Apr 7, 2026
Maintains: Buy
Price Target: $80 → $100
Current: $66.82
Upside: +49.66%
Aura Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $22
Current: $6.96
Upside: +216.09%
Terns Pharmaceuticals
Mar 25, 2026
Downgrades: Neutral
Price Target: $60 → $53
Current: $52.95
Upside: +0.09%
Sutro Biopharma
Mar 24, 2026
Upgrades: Buy
Price Target: $10 → $28
Current: $33.59
Upside: -16.64%
Erasca
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $19.15
Upside: +4.44%
Foghorn Therapeutics
Mar 10, 2026
Reiterates: Buy
Price Target: $13
Current: $5.21
Upside: +149.52%
enGene Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $25
Current: $7.20
Upside: +247.22%
Scholar Rock Holding
Mar 3, 2026
Reiterates: Buy
Price Target: $58
Current: $46.29
Upside: +25.30%
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $7.29
Upside: +105.76%
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $23.49
Upside: +70.29%
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $4.99
Upside: +360.92%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.83
Upside: +381.93%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.31
Upside: +434.35%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $21.00
Upside: +90.48%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $10.08
Upside: +296.83%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $6.29
Upside: +265.66%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $54.02
Upside: +94.37%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $11.01
Upside: +81.65%